Parenteral Soybean Oil Induces Hepatosteatosis Despite Addition of Fish Oil in a Mouse Model of Intestinal Failure–Associated Liver Disease

• Published in: JPEN. Journal of parenteral and enteral nutrition 2018-02, Vol.42 (2), p.403-411
• Main Authors: Nandivada, Prathima, Fell, Gillian L., Pan, Amy H., Nose, Vania, Mitchell, Paul D., Gura, Kathleen M., Puder, Mark
• Format: Article
• Language: English
• Subjects: fat emulsion; fish oil; hepatosteatosis; intestinal failure–associated liver disease; mixed fat emulsion; soybean oil
• ISSN: 0148-6071; 1941-2444
• DOI: 10.1177/0148607117695249

Background: Replacement of parenteral soybean oil (SO) with fish oil (FO) is an effective therapy for intestinal failure–associated liver disease (IFALD) in children. However, practitioners remain concerned about the risk of essential fatty acid deficiency (EFAD) and sometimes treat IFALD with a combination of 50% SO and 50% FO emulsions. The purpose of this study was to determine if mixing 50% SO and 50% FO emulsions would prevent hepatosteatosis in a murine model of parenteral nutrition (PN)–induced hepatosteatosis. Methods: C57BL/6 mice were randomized to receive oral PN with parenteral saline, FO, SO, or a mixture of 50% FO and 50% SO for 19 days. Fatty acid analysis, histologic evaluation, Nonalcoholic Steatohepatitis Clinical Research Network (NSCRN) scores, and reverse‐transcriptase polymerase chain reaction for key lipogenic genes were performed. Results: The PN + saline group was the only group with EFAD, with a serum and hepatic triene/tetraene ratio of 0.53. NSCRN scores were highest in the PN + SO group (5.5; 95% confidence interval [CI], 4.9–6.1), followed by the PN + FO/SO (4.5; 95% CI, 3.5–5.5) group, with the lowest score in the PN + FO (2.0; 95% CI, 1.1–2.9) group. Acetyl CoA carboxylase α and acetyl CoA carboxylase β expression was lower in the PN + FO group than in the PN + FO/SO or PN + SO groups. Conclusions: Our data demonstrate that a mixed fat emulsion of 50% SO and 50% FO is inferior to 100% FO in reducing hepatosteatosis in this model. These data suggest that use of parenteral SO with parenteral FO, in a 1:1 ratio, may still contribute to liver injury, although it is less hepatotoxic than pure SO.